Circulating biomarkers for the diagnosis of ADa.
Sl. no. | Biomarker class | Target biomarkers | Remarks | Specificity (%) | Sensitivity (%) | Sample size | Ref. |
---|---|---|---|---|---|---|---|
1 | CSF and blood | ||||||
Aβ | Aβ42/40 | Decreased significantly, correlates with Aβ positivity | 100 | 84 | 45 | 91 | |
Composite model | Model from Aβ42, 40 and ratio diagnose disease with 90% accuracy | 81 | 96.7 | N =121 and N = 252 | 92 | ||
Tau | t-tau and p-tau | Increased | 80 | 80 | 97 | 94 | |
p-tau-181 | Increased, discriminate MCI and AD. Correlates with tau PET positivity, atrophy, and CSF biomarkers | 87 | 92 | N1 = 182 | 95 | ||
N2 = 344 | |||||||
p-tau-217 | Increased 6-fold in AD correlates with Aβ and tau positivity, early diagnosis of AD | 91 | 91 | 194 + 32 | 96 | ||
p-tau-231 | Increased in the early stage, outperforms p-tau-181, correlates with Aβ and tau deposition | — | — | 38 + 313 | 99 | ||
Protein biomarkers | Neurogranin | Increased in CSF and correlates with CSF biomarkers, atrophy and brain Aβ load | 60 | 79 | 302 | 100 | |
Synaptotagmin | Increased, discriminate MCI and AD | — | — | 39 + 78 | 102 | ||
sTREM | Increased, correlates with CSF Aβ and tau biomarkers, atrophy and brain Aβ load | — | — | 155 + 93 | 103 | ||
YKL-40 | Increased, correlates with Aβ deposition and memory deficits | 85 | 85 | 318 | 104 | ||
Nf-L | Increased, correlates with CSF t-tau and p-tau, cortical atrophy, Aβ deposition and brain metabolism. Discriminate MCI and AD cases | CSF-187 | 106 | ||||
Ser-405 | |||||||
N = 196 | |||||||
RNA biomarkers | BACE1 lcnRNA miRNA panels | Increased in plasma | 61.3 | 87.5 | 134 | 109 | |
Exosome 7 miRNA panel diagnoses with 89% accuracy (miR-185-5p, miR-342-3p, miR-141-3p, miR342-5p, miR-23b-3p, miR-338-3p and miR-3613-3p) | — | — | 70 | 110 | |||
Plasma 6 miRNA panel (miR-185-5p, miR-342-3p, miR-141-3p, miR342-5p, miR-23b-3p, miR-338-3p and miR-3613-3p) | 78 | 75 | 50 | 111 | |||
CSF 6–7 miRNA panel, correlates with CSF biomarkers and the cognitive score | — | — | 118 | 112 | |||
Protein and metabolite panel | Multiple protein panel in blood | 18 biomolecule alteration was identified (2 cohorts) | 93 | 85 | N1 = 961 | 113 | |
85 | 80 | N2 = 170 | |||||
3 protein panel | Plasma Aβ42/40, pTau-217 and Nf-L diagnose AD and correlates with cognitive changes | — | — | 435 | 114 | ||
4 protein panel | Blood exosomal GAP43, neurogranin, SNAP25 and synaptotagmin-1 are early diagnosis biomarkers | — | — | 320 | 116 | ||
Spingomyelin metabolites | 26 metabolites, diagnose AD with an accuracy of 83.33% | 80 | 86.67 | N1 = 44 | 117 | ||
N2 = 767 | |||||||
N3 = 207 | |||||||
2 | Saliva | ||||||
Aβ | Aβ42 | Increased and specific to AD over PD | — | — | 22 | 118 | |
Tau | p-tau/t-tau | Increased | — | — | 59 | 119 | |
p-tau-396/t-tau | Increased, no correlation with other biomarkers | 50 | 73 | 148 | 120 | ||
Lf | Full length Lf | Decreased, outperforms CSF biomarkers. Other studies contradict and changes are inconsistent | 100 | 100 | N1 = 274 | 121 | |
98.6 | 100 | N2 = 127 | |||||
3 | Urine | ||||||
Protein | SPP1, GSN and IGFBP7 | Increased, MS techniques were used to screen and confirmed by ELISA | — | — | 40 | 125 | |
4 | Tear | ||||||
Protein | Lipocalin-1, dermcidin, lysozyme-C and lacritin | Proteins are significantly altered in AD over healthy individuals | 77 | 81 | 23 | 124 | |
Significant increase in the tear total protein and flow rate |
p-tau: phosphorylated tau and t-tau: total tau.